Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Psychol Med ; 45(10): 2045-56, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25612927

RESUMO

BACKGROUND: Course and predictors of persistence of attention deficit hyperactivity disorder (ADHD) in adults are still largely unknown. Neurobiological and clinical differences between child and adult ADHD raise the need for follow-up studies of patients diagnosed during adulthood. This study investigates predictors of ADHD persistence and the possibility of full remission 7 years after baseline assessment. METHOD: A 7-year follow-up study of adults with ADHD (n = 344, mean age 34.1 years, 49.9% males) was conducted. Variables from different domains (social demographics, co-morbidities, temperament, medication status, ADHD measures) were explored with the aim of finding potential predictors of ADHD persistence. RESULTS: Retention rate was 66% (n = 227). Approximately a third of the sample (n = 70, 30.2%) did not maintain ADHD criteria and 28 (12.4%) presented full remission (<4 symptoms), independently of changes in co-morbidity or cognitive demand profiles. Baseline predictors of diagnostic persistence were higher number of inattention symptoms [odds ratio (OR) 8.05, 95% confidence interval (CI) 2.54-25.45, p < 0.001], number of hyperactivity/impulsivity symptoms (OR 1.18, 95% CI 1.04-1.34, p = 0.01), oppositional defiant disorder (OR 3.12, 95% CI 1.20-8.11, p = 0.02), and social phobia (OR 3.59, 95% CI 1.12-11.47, p = 0.03). CONCLUSIONS: Despite the stage of brain maturation in adults suggests stability, approximately one third of the sample did not keep full DSM-IV diagnosis at follow-up, regardless if at early, middle or older adulthood. Although full remission is less common than in childhood, it should be considered as a possible outcome among adults.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Transtorno do Deficit de Atenção com Hiperatividade/psicologia , Estimulantes do Sistema Nervoso Central/uso terapêutico , Metilfenidato/uso terapêutico , Adolescente , Adulto , Idoso , Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico , Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia , Brasil/epidemiologia , Comorbidade , Seguimentos , Hospitais de Ensino , Humanos , Entrevista Psicológica , Pessoa de Meia-Idade , Fobia Social/complicações , Fobia Social/psicologia , Análise de Regressão , Indução de Remissão , Resultado do Tratamento , Adulto Jovem
2.
J Environ Manage ; 120: 138-47, 2013 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-23524327

RESUMO

Can markets assist by providing support for ecological restoration, and if so, under what conditions? The first step in addressing this question is to develop a consistent methodology for economic evaluation of ecological restoration projects. A risk analysis process was followed in which a system dynamics model was constructed for eight diverse case study sites where ecological restoration is currently being pursued. Restoration costs vary across each of these sites, as do the benefits associated with restored ecosystem functioning. The system dynamics model simulates the ecological, hydrological and economic benefits of ecological restoration and informs a portfolio mapping exercise where payoffs are matched against the likelihood of success of a project, as well as a number of other factors (such as project costs and risk measures). This is the first known application that couples ecological restoration with system dynamics and portfolio mapping. The results suggest an approach that is able to move beyond traditional indicators of project success, since the effect of discounting is virtually eliminated. We conclude that systems dynamic modelling with portfolio mapping can guide decisions on when markets for restoration activities may be feasible.


Assuntos
Conservação dos Recursos Naturais/métodos , Monitoramento Ambiental/métodos , Modelos Teóricos , Medição de Risco , África do Sul
3.
Mol Psychiatry ; 17(5): 520-6, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-21403674

RESUMO

Although several studies have demonstrated an association between the 7-repeat (7R) allele in the 48-bp variable number of tandem repeats (VNTRs) in the exon 3 at dopamine receptor D4 (DRD4) gene and attention-deficit/hyperactivity disorder (ADHD), others failed to replicate this finding. In this study, a total of 786 individuals with ADHD were genotyped for DRD4 exon 3 VNTR. All 7R homozygous subjects were selected for VNTR re-sequencing. Subjects homozygous for the 4R allele were selected paired by age, ancestry and disorder subtypes in order to have a sample as homogeneous as possible with 7R/7R individuals. Using these criteria, 103 individuals (66 with ADHD and 37 control individuals) were further investigated. An excess of rare variants were observed in the 7R alleles of ADHD patient when compared with controls (P=0.031). This difference was not observed in 4R allele. Furthermore, nucleotide changes that predict synonymous and non-synonymous substitutions were more common in the 7R sample (P=0.008 for total substitutions and P=0.043 for non-synonymous substitutions). In silico prediction of structural/functional alterations caused by these variants have also been observed. Our findings suggest that not only repeat length but also DNA sequence should be assessed to better understand the role of DRD4 exon 3 VNTR in ADHD genetic susceptibility.


Assuntos
Alelos , Transtorno do Deficit de Atenção com Hiperatividade/genética , Predisposição Genética para Doença/genética , Variação Genética/genética , Receptores de Dopamina D4/genética , Adulto , Sequência de Aminoácidos/genética , Sequência de Bases , Criança , Éxons/genética , Feminino , Genótipo , Humanos , Masculino , Repetições Minissatélites/genética , Dados de Sequência Molecular
4.
Eur Psychiatry ; 27(5): 309-13, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20934311

RESUMO

Since approximately 70% of adult patients with attention-deficit/hyperactivity disorder (ADHD) have at least one comorbid disorder, rating of impairment specifically attributable to ADHD is a hard task. Despite the evidence linking environmental adversities with negative outcomes in ADHD, life events measures have not been used to rate the disorder impairment. The present study tested for the first time the hypothesis that increased ADHD severity is associated with an increase in negative recent life events, independently of comorbidity status. The psychiatric diagnoses of 211 adult ADHD outpatients were based on DSM-IV criteria assessed through structured interviews (K-SADS-E for ADHD and ODD, MINI for ASPD and SCID-IV-R for other comorbidities). ADHD severity was evaluated with the Swanson, Nolan and Pelham rating scale (SNAP-IV) and recent life events with the Life Experience Survey. Higher SNAP-IV inattention and hyperactivity scores, female gender, lower socioeconomic status and the presence of comorbid mood disorders were associated with negative life events. Poisson regression models with adjustment for possible confounders confirmed the effect of inattention and hyperactivity severity on negative life events. Our results suggest that the negative life events experienced by these patients are associated to the severity of ADHD independently from comorbid psychiatric disorders.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/psicologia , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/psicologia , Acontecimentos que Mudam a Vida , Transtornos do Humor/psicologia , Qualidade de Vida/psicologia , Adulto , Transtorno do Deficit de Atenção com Hiperatividade/complicações , Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/complicações , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/diagnóstico , Manual Diagnóstico e Estatístico de Transtornos Mentais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos do Humor/complicações , Índice de Gravidade de Doença , Fatores Sexuais , Fatores Socioeconômicos , Inquéritos e Questionários
5.
Neurosci Lett ; 502(3): 143-6, 2011 Sep 20.
Artigo em Inglês | MEDLINE | ID: mdl-21741441

RESUMO

Schizophrenia (SZ) is a chronic severe mental disorder. Increased inflammatory processes have been shown in acute and chronic SZ. Apoptotic processes may alter the neuronal network and are involved in the pathogenesis of several neurodegenerative diseases, such as SZ. Annexin-V seems to have a role on inhibition of pro-inflammatory activities during apoptosis. Tumor necrosis factor (TNF-alpha) is a cytokine involved in systemic inflammation and is a member of a group of cytokines which stimulate acute phase reactions. A chronic immune activation in SZ has been shown. The aim of this study was to compare annexin-V and TNF-alpha serum levels in chronic medicated patients with SZ and healthy controls. Thirty-eight outpatients from the HCPA Schizophrenia Program and 38 healthy controls were enrolled to this study protocol. Annexin-V and TNF-alpha serum levels were measured with ELISA. Serum annexin-V levels were significantly higher in patients with SZ than in controls (p<0.001) and TNF-alpha significantly lower (p<0.001). The present result of increased annexin-V and decreased serum levels of TNF-alpha compared to controls may be a result of the stabilization phase of psychosis and a reduction in metabolic brain aggression. In this complex picture, increased levels of annexin-V and decreased levels of TNF-alpha in our sample would be explained by illness stability and chronic treatment. Our findings support the hypothesis of a state dependant process of inflammation in SZ. Further prospective studies to clarify the findings described in this paper are needed.


Assuntos
Anexina A5/sangue , Antipsicóticos/uso terapêutico , Encéfalo/metabolismo , Esquizofrenia/sangue , Fator de Necrose Tumoral alfa/sangue , Adulto , Anexina A5/fisiologia , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Doença Crônica , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/fisiologia , Metabolismo Energético/efeitos dos fármacos , Metabolismo Energético/fisiologia , Feminino , Humanos , Inflamação/imunologia , Inflamação/metabolismo , Inflamação/patologia , Masculino , Pessoa de Meia-Idade , Esquizofrenia/patologia , Esquizofrenia/terapia , Resultado do Tratamento , Fator de Necrose Tumoral alfa/fisiologia , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/fisiologia
6.
J Psychopharmacol ; 23(8): 985-7, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18583441

RESUMO

The psychopathologies underlying affective disorders are thought to involve persistent changes in the expression and function of both mineralocorticoid receptors and glucocorticoid receptors in the hippocampus. In addition, exposure to stressful stimuli can precipitate episodes in vulnerable individuals. The aim of this study is to determine if spironolactone as an adjunctive therapy is effective in improving residual symptoms in bipolar disorder. Four cases of euthymic bipolar disorder (BD) patients were treated with spironolactone as an adjunctive therapy in a private treatment sector. All patients met the DSM-IV diagnosis criteria for bipolar disorder. Clinical response was assessed retrospectively using the Clinical Global Impression Scale for Improvement. Spironolactone was effective in all patients. The four cases illustrate a clinical response to residual symptoms and improvement in stress response after use of spironolactone as an adjunctive therapy in BD. This pilot case series suggests reducing in residual symptoms, with spironolactone as an adjunctive therapy in these DSM-IV BD patients. Mineralocorticoid receptors antagonists' role in reducing stress-induced symptoms deserves further investigation through placebo-controlled trials.


Assuntos
Transtorno Bipolar/tratamento farmacológico , Antagonistas de Receptores de Mineralocorticoides , Espironolactona/uso terapêutico , Estresse Psicológico/tratamento farmacológico , Adulto , Transtorno Bipolar/psicologia , Feminino , Humanos , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Sistema Hipófise-Suprarrenal/efeitos dos fármacos
7.
J Neural Transm (Vienna) ; 114(12): 1631-6, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17690945

RESUMO

The present study investigates possible associations between the 5-HTT control region polymorphism (5-HTTLPR) with adult ADHD, including subtypes, severity, temperament profile and comorbidities. The polymorphic site was genotyped in 312 adult patients with ADHD and 236 controls, all of them Brazilians of European descent. The interviews followed the DSM-IV criteria, using the K-SADS-E for ADHD and oppositional defiant disorder, SCID-I and MINI for comorbidities and the TCI for temperament dimensions. The 5-HTTLPR polymorphism was not associated with ADHD. Carriers of the S allele presented slightly higher inattention and novelty seeking scores, and a higher frequency of drug dependence. These differences do not persist after correction for multiple comparisons. These results suggest that the 5-HTTLPR polymorphism does not have a direct role in the predisposition to adult ADHD. There is suggestive evidence for a small effect in some behavioral phenotypes related to ADHD.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/genética , Polimorfismo Genético , Proteínas da Membrana Plasmática de Transporte de Serotonina/genética , Adulto , Feminino , Frequência do Gene , Predisposição Genética para Doença , Genótipo , Humanos , Masculino , Fenótipo , Reação em Cadeia da Polimerase
8.
Neurosci Lett ; 414(1): 61-4, 2007 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-17289263

RESUMO

Adenosine is an important modulator of the nervous system that has been implicated in the pathophysiology of schizophrenia. We studied peripheral adenosine metabolism by determining the activity of serum adenosine deaminase, which converts adenosine into inosine, and 5'-nucleotidase, which converts AMP into adenosine, in 26 DSM-IV male schizophrenic patients under antipsychotic monotherapy and 26 healthy volunteers balanced for age and race. Schizophrenic patients treated either with typical antipsychotics or clozapine showed increased serum adenosine deaminase activity compared to controls (controls=18.96+/-4.61 U/l; typical=25.09+/-10.98 U/l; clozapine=30.32+/-10.83 U/l; p<0.05, ANOVA) and 5'-nucleotidase activity was also increased in patients on clozapine. After adjusting for confounding factors, adenosine deaminase, but not 5'-nucleotidase, alterations remained significant particularly in the clozapine group. This result suggests that either altered adenosine metabolism is present in schizophrenic patients or is influenced by treatment with antipsychotics, particularly clozapine.


Assuntos
Adenosina Desaminase/sangue , Adenosina/metabolismo , Encéfalo/efeitos dos fármacos , Encéfalo/enzimologia , Esquizofrenia/tratamento farmacológico , Esquizofrenia/enzimologia , 5'-Nucleotidase/sangue , 5'-Nucleotidase/efeitos dos fármacos , Adenosina Desaminase/efeitos dos fármacos , Adolescente , Adulto , Antipsicóticos/farmacologia , Biomarcadores/análise , Biomarcadores/sangue , Encéfalo/fisiopatologia , Clozapina/farmacologia , Resistência a Medicamentos/efeitos dos fármacos , Resistência a Medicamentos/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Esquizofrenia/sangue , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/fisiologia
10.
Int Clin Psychopharmacol ; 16(4): 235-7, 2001 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-11459338

RESUMO

Adenosine has been proposed to contribute to the pathophysiology of schizoprenia and as a target for therapeutic intervention. In the lack of direct adenosine agonists, allopurinol may indirectly elevate adenosine levels by inhibiting degradation of purines. We report two cases of poorly responsive schizophrenic patients who improved considerably with add-on allopurinol 300 mg/day. Their clear clinical improvement warrant further investigation of allopurinol, as well as other purinergic strategies, for the treatment of schizophrenia.


Assuntos
Alopurinol/administração & dosagem , Antipsicóticos/administração & dosagem , Esquizofrenia/tratamento farmacológico , Adulto , Interações Medicamentosas , Quimioterapia Combinada , Humanos , Masculino , Escalas de Graduação Psiquiátrica , Psicologia do Esquizofrênico , Resultado do Tratamento
12.
J Psychiatr Res ; 35(1): 11-4, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11287051

RESUMO

S100B protein, a calcium binding protein produced and released by glial cells, has been used as a sensitive marker of brain damage. Previous studies have found alterations in peripheral S100B levels in schizophrenic patients on medication. We compared serum S100B levels of 20 medication-free DSM-IV schizophrenic patients and 20 age-gender matched healthy controls. Schizophrenic patients presented higher serum S100B levels (mean 0.120 ng/ml+/-S.D. 0.140) compared to controls (mean 0.066 ng/ml+/-S.D. 0.067; P=0.014) and there was a negative correlation with illness duration (r=-0.496, P=0.031). The results of this study indicate that serum S100B levels may be a state marker of a limited neurodegenerative process, particularly in the early course of schizophrenia or, at least, in a subgroup of schizophrenic patients.


Assuntos
Proteínas S100/sangue , Esquizofrenia/metabolismo , Adolescente , Adulto , Encéfalo/metabolismo , Encéfalo/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Neurodegenerativas/metabolismo , Doenças Neurodegenerativas/patologia , Neuroglia/metabolismo
13.
Braz J Med Biol Res ; 34(2): 155-63, 2001 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11175490

RESUMO

The authors review environmental and neurodevelopmental risk factors for schizophrenic disorders, with emphasis on minor physical anomalies, particularly craniofacial anomalies and dermatoglyphic variations. The high prevalence of these anomalies among schizophrenic subjects supports the neurodevelopmental theory of the etiology of schizophrenia, since they suggest either genetically or epigenetically controlled faulty embryonic development of structures of ectodermal origin like brain and skin. This may disturb neurodevelopment that in turn may cause these subjects to be at increased risk for the development of schizophrenia and related disorders. The precise confirmation of this theory, at least in some cases, will provide further understanding of these illnesses, allowing easy and inexpensive identification of subjects at risk and providing guidelines for the development of new pharmacological interventions for early treatment and even for primary prevention of the illness.


Assuntos
Anormalidades Craniofaciais/complicações , Deficiências do Desenvolvimento/complicações , Esquizofrenia/etiologia , Meio Social , Encefalopatias/patologia , Criança , Dermatoglifia , Feminino , Humanos , Masculino , Estado Nutricional , Complicações do Trabalho de Parto , Gravidez , Complicações Infecciosas na Gravidez , Fatores de Risco , Estações do Ano
14.
Braz. j. med. biol. res ; 34(2): 155-163, Feb. 2001.
Artigo em Inglês | LILACS | ID: lil-281593

RESUMO

The authors review environmental and neurodevelopmental risk factors for schizophrenic disorders, with emphasis on minor physical anomalies, particularly craniofacial anomalies and dermatoglyphic variations. The high prevalence of these anomalies among schizophrenic subjects supports the neurodevelopmental theory of the etiology of schizophrenia, since they suggest either genetically or epigenetically controlled faulty embryonic development of structures of ectodermal origin like brain and skin. This may disturb neurodevelopment that in turn may cause these subjects to be at increased risk for the development of schizophrenia and related disorders. The precise confirmation of this theory, at least in some cases, will provide further understanding of these illnesses, allowing easy and inexpensive identification of subjects at risk and providing guidelines for the development of new pharmacological interventions for early treatment and even for primary prevention of the illness


Assuntos
Humanos , Gravidez , Feminino , Anormalidades Craniofaciais/complicações , Doenças do Sistema Nervoso/complicações , Esquizofrenia/etiologia , Meio Social , Dermatoglifia , Complicações do Trabalho de Parto , Complicações Infecciosas na Gravidez , Fatores de Risco , Estações do Ano
15.
J Psychopharmacol ; 14(1): 81-3, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10757259

RESUMO

The impairment of the purinergic system, characterized by reduced adenosinergic activity, has been implicated in the neurobiology of aggressive behaviour. Since there are no direct adenosine agonists available for human use, inhibition of purine degradation by allopurinol was conceived as a possible strategy. We report two cases of adults with refractory aggressive behaviour due to a neurological condition (one mainly with self-inflicted behaviour) with dramatic response to therapy with allopurinol, 300 mg/day p.o. These preliminary results reinforce the involvement of the purinergic system in the neurobiology of aggression, warranting further testing of allopurinol as a new treatment for aggressive and self-inflicted behaviours.


Assuntos
Agressão/efeitos dos fármacos , Alopurinol/administração & dosagem , Inibidores Enzimáticos/administração & dosagem , Transtornos Neurocognitivos/tratamento farmacológico , Complicações Pós-Operatórias/tratamento farmacológico , Comportamento Autodestrutivo/tratamento farmacológico , Administração Oral , Adulto , Alopurinol/efeitos adversos , Astrocitoma/radioterapia , Astrocitoma/cirurgia , Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/cirurgia , Terapia Combinada , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/efeitos adversos , Feminino , Humanos , Deficiência Intelectual/diagnóstico , Deficiência Intelectual/tratamento farmacológico , Masculino , Meningite/complicações , Transtornos Neurocognitivos/diagnóstico , Lobo Parietal/efeitos da radiação , Lobo Parietal/cirurgia , Complicações Pós-Operatórias/diagnóstico , Radioterapia Adjuvante , Comportamento Autodestrutivo/diagnóstico
16.
Rev. bras. enferm ; 49(4): 625-38, out.-dez. 1996.
Artigo em Português | LILACS, BDENF - Enfermagem | ID: lil-217006

RESUMO

Considerando que os Direitos do Paciente devem ser respeitados por todos os profissionais da área de saúde, desenvolveu-se esta pesquisa exploratória a fim de analisar o posicionamento de médicos e enfermeiros diante da vivência desses princípios. Aplicou-se o método descritivo e a técnica de investigaçäo social, no Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, no período de setembro a dezembro de 1994, junto a uma amostra aleatória composta por 26 enfermeiros e 24 médicos. Utilizou-se um questionário com 30 questöes que foi distribuído aos mesmos para respondê-lo. O marco referencial compreendeu os princípios éticos e legais que determinaram os direitos humanos, a atitude dos profissionais de saúde no relacionamento com os clientes e os próprios direitos do paciente...


Assuntos
Humanos , Defesa do Paciente , Ética em Enfermagem , Ética Médica , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...